Key result
Genetic testing identifies disease-causing mutations in ~40% of patients with suspected familial hypercholesterolemia.
Observational (n=1,053)
Answers are grounded in this paper and cite their sources.
The lipid disorder familial hypercholesterolemia (FH) predisposes to cardiovascular disease. With a prevalence of approximately one in 500 in the general Caucasian population, FH is one of the most frequent single-gene disorders. As the mutational spectra vary between populations, it is crucial to identify the mutations in a given population in order to implement a molecular genetic screening strategy. A total of 1053 referred individuals with clinical signs of FH were investigated, and mutations were identified in 425 individuals. Fifty-four different mutations were identified, of which 13 are novel. The five most frequent mutations accounted for 56.3% of all disease-causing mutations. The majority of the remaining mutations were of a private nature only encountered in single families. In this study, a reliable molecular genetic screening protocol was established, and the relevance of performing presymptomatic genetic analysis as part of a preventive strategy was documented. We have acquired knowledge of the mutational spectra in the Danish population and thus will be able to trace mutations in their relatives through our index cases.
No takes yet. Share an insight, caveat, or question.
Brusgaard et al. (2006) conducted an observational in Familial hypercholesterolemia (n=1,053). Molecular genetic analysis was evaluated on Identification of disease-causing mutations. Molecular genetic analysis of 1,053 Danish individuals with clinical signs of familial hypercholesterolemia identified disease-causing mutations in 425 individuals (40.4%).
Synapse has enriched 10 related papers. Consider them for comparative context: